CHICAGO, Feb. 26, 2020 /PRNewswire/ -- Third Eye Health, the nation's largest post-acute telehealth provider, announced today that its solution has been integrated with

TARRYTOWN, N.Y., Feb. 26, 2020 /PRNewswire/ -- Recognizing the growing importance of quality behavioral health programs for payers, The IMA Group (IMA) announced today the acquisition of Ps

VANCOUVER, Feb. 26, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its financial results for 2019 will be released

CAMBRIDGE, Mass., Feb. 26, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, Douglas E. Onsi, Chief Financia

CARLSBAD, Calif., Feb. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter and full year 2019 and recent business highlights.

CHICAGO, Feb. 26, 2020 /PRNewswire/ -- Hillrom (NYSE: HRC) announced today that its board of directors declared a 5 percent increase in the company's quarterly dividend rate, from the previous rate of $0.21 per share to $0.22 per share. The fiscal second quarter 2020 quarterly dividend is payable on March 31, 2020, to shareholders of re

NEW YORK, Feb. 26, 2020 /PRNewswire/ -- The promise and potential risks of machine learning and other technology will be examined by experts at the 29th Healthcare Risk Management / Patient Safety Conference on Wednesday, March 11, at the New York Marriott Marquis.

DENVER, Feb. 26, 2020 /PRNewswire/ -- DaVita Kidney Care

— Strong Operational Performance Led by Year-over-Year Double-Digit-Percentage Revenue Growth in Sterile Injectables Segment and in Specialty Products Portfolio of Branded Pharmaceuticals Segment —— Full-Year 2020 Financial Guidance Provided for Revenue, Adjusted Diluted Net Income per Share from Continuing Operations and Adjusted EBITDA —

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2019. Full year net revenue decreased 11% to $1,449 million